Published clinical trial data describe weekly dose-escalation protocols ranging from sub-milligram to low-milligram levels in controlled study populations
This support is particularly relevant for individuals with known toxic exposures or conditions that interfere with normal detox mechanisms
Motivated by these previous reports and the simplicity of the HIP approach, we evaluated the HIP of GSH-AuNCs with DDA (we avoided the use of quaternary ammonium phase transfer agents due to their toxicity)
43,44 Interpatient variability in absorption, distribution, metabolism, and excretion affects drug bioavailability and exposure
CJC-1295 without DAC (also called Mod GRF 1-29) lacks the linker and clears within approximately 30 minutes, producing a sharper, pulse-aligned signal
References [1] Lau, D.C.W., et al